From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
Trade namesEucrisa, /jˈkrɪsə/ yoo-KRIS
Routes of
Topical (ointment)
ATC code
Legal status
Legal status
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.225.309 Edit this at Wikidata
Chemical and physical data
Molar mass251.045 g/mol g·mol−1
3D model (JSmol)

Crisaborole, sold under the brand name Eucrisa, is a nonsteroidal topical medication used for the treatment of mild-to-moderate atopic dermatitis (eczema) in people two years or older.[1][2] It was approved by U.S. Food and Drug Administration on Dec 14, 2016[3] and June 6, 2018 by Health Canada[4].

Side effects[edit]

At the site of application, crisaborole may cause burning or stinging. Rarely, there may be an allergic reaction.[5]



Crisaborole is a phosphodiesterase-4 inhibitor, mainly acting on phosphodiesterase 4B (PDE4B), which causes inflammation.[6] Chemically, crisaborole is a phenoxybenzoxaborole.[6] Inhibition of PDE4B appears to suppress the release of tumor necrosis factor alpha (TNFα), interleukin-12 (IL-12), IL-23 and other cytokines, proteins believed to be involved in the immune response and inflammation.[6]


Crisaborole (chemical name: 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)oxy]benzonitrile) is a member of the class of benzoxaboroles characterized by the presence of a boronic acid hemiester with a phenolic ether and a nitrile.[7] Crisaborole crystallizes into two polymorphs that differ in the conformation of the oxaborole ring. A cocrystal with 4,4'-bipyridine has been prepared and studied by X-ray crystallography.[8]


Crisaborole was developed by Anacor Pharmaceuticals for the topical treatment of psoriasis.[9][6][10] During preclinical and clinical development, crisaborole was called AN2728 and PF-06930164.[11]

See also[edit]


  1. ^ "FDA Approves Eucrisa for Eczema". U.S. Food and Drug Administration. 14 December 2016.
  2. ^ "Eucrisa (crisaborole) Ointment, 2%, for Topical Use. Full Prescribing Information". Anacor Pharmaceuticals, Inc. Palo Alto, CA 94303 USA. Retrieved 17 December 2016.
  3. ^ "FDA approves Eucrisa for eczema" (Press release). U.S. Food and Drug Administration. December 14, 2016.
  4. ^ Government of Canada. "Regulatory Decision Summary - Eucrisa - Health Canada". Health Canada. Archived from the original on 2019-09-14. Retrieved 2019-09-14.
  5. ^ "PRODUCT MONOGRAPH" (PDF). Government of Canada. 2018-06-07. Archived (PDF) from the original on 2019-04-07. Retrieved 2019-04-07.
  6. ^ a b c d Moustafa, F; Feldman, SR (16 May 2014). "A Review of Phosphodiesterase-Inhibition and the Potential Role for Phosphodiesterase 4-Inhibitors in Clinical Dermatology" (PDF). Dermatology Online Journal. 20 (5): 22608. PMID 24852768.
  7. ^ "WHO Drug Information, Vol. 29, No. 3, 2015. International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 74" (PDF). World Health Information. p. 391. Retrieved 26 April 2016.
  8. ^ Campillo-Alvarado, Gonzalo; Didden, Tighe D.; Oburn, Shalisa M.; Swenson, Dale C.; MacGillivray, Leonard R. (2018). "Exploration of Solid Forms of Crisaborole: Crystal Engineering Identifies Polymorphism in Commercial Sources and Facilitates Cocrystal Formation". Crystal Growth & Design. 18 (8): 4416–4419. doi:10.1021/acs.cgd.8b00375. ISSN 1528-7483.
  9. ^ Nazarian, R; Weinberg, JM (November 2009). "AN-2728, a PDE4 Inhibitor for the Potential Topical Treatment of Psoriasis and Atopic Dermatitis". Current Opinion in Investigational Drugs. 10 (11): 1236–42. PMID 19876791.
  10. ^ Spreitzer, H (16 August 2016). "Neue Wirkstoffe: Crisaborol". Österreichische Apotheker-Zeitung (in German) (17/2016).
  11. ^ "Crisaborole". AdisInsight. Retrieved 24 July 2017.